Taysha Gene Therapies Inc (TSHA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.34B
Last updated: Nov 17, 2026 at 11:06 AM ET
Taysha Gene Therapies Inc (TSHA) Stock Forecast
Analysts expect Taysha Gene Therapies (TSHA) to earn -$0.39 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.71M. Of 13 analysts, 13 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 1.77, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 23.1% |
| Buy | 10 | 76.9% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 784.9%.
- Fiscal year ending Dec 31, 2026
- -$0.39
- EPS consensus, revenue $2.71M
- Fiscal year ending Dec 31, 2027
- -$0.40
- EPS consensus, revenue $23.98M
- Next report
- Mar 17, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.39 | -$0.43 to -$0.35 | 3 | $2.71M | N/A | 7 |
| Dec 31, 2027 | -$0.40 | -$0.55 to -$0.31 | 4 | $23.98M | N/A | 5 |
Quarterly Estimates
The EPS consensus rises from -$0.13 for the quarter ending Dec 31, 2026 to -$0.10 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.13 | -$0.15 to -$0.12 | 14 | $382500 | N/A | 13 |
| Mar 31, 2027 | -$0.10 | -$0.13 to -$0.08 | 3 | $1.60M | N/A | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 8 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 3 |
| Fiscal year ending Dec 31, 2027 | 0 | 3 |
| Quarter ending Mar 31, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.47.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.39 | -$0.47 | -$0.47 | -$0.47 | -$0.47 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.40 | -$0.46 | -$0.46 | -$0.46 | -$0.48 | N/A |
| Quarter ending Mar 31, 2027 | -$0.10 | -$0.12 | -$0.12 | -$0.12 | -$0.13 | N/A |
Frequently Asked Questions About TSHA
What is the TSHA stock forecast?
Consensus analyst estimates put Taysha Gene Therapies's EPS at -$0.39 for the fiscal year ending Dec 31, 2026, on revenue of $2.71M. The consensus rating from 13 analysts is Buy.
How do analysts rate TSHA stock?
Of 13 analysts covering Taysha Gene Therapies, 3 rate it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TSHA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.39, with estimates from -$0.43 to -$0.35 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.40, with estimates from -$0.55 to -$0.31 from 4 analysts.
What revenue do analysts expect from Taysha Gene Therapies next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.71M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $23.98M.
How many analysts cover TSHA?
13 analysts rate Taysha Gene Therapies stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TSHA pages: Overview, Earnings, Forecast, Financials, Competitors